Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation
By Xiaoyaowan
Hutchison MediPharma’s targeted anticancer drug: fruquintinib has recently received the Fast Track designation granted by the FDA for the treatment of patients with metastatic colorectal cancer (mCRC).
Receiving the Fast Track designation, one of the accelerated review and approval procedures established by the FDA, means the pharmaceutical product will receive more attention from the FDA in the R&D and registration processes so that the new drug R&D and marketing time will be shortened. The FDA’s Fast Track designation received by Hutchison MediPharma’s fruquintinib will undoubtedly accelerate the marketing of the drug in the U.S. to bring a new therapeutic regimen to overseas mCRC patients.
Visit PharmaSources.com to read more:
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation
CPhI China 2020 To Be Postponed to Dec. 16-18th,
Register as Visitor to the 20th Edition of CPhI China!
-----------------------------------------------------------------------
Editor's Note:
To become a freelance writer of PharmaSources.com,
welcome to send your CV and sample works to us,
Email: [email protected].